Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CNTA 
Centessa Pharmaceuticals PLC ADR (CNTA)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/29/2025: CNTA (4-star) is a STRONG-BUY. BUY since 36 days. Simulated Profits (5.59%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $33.23
1 Year Target Price $33.23
| 7 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 149.51% | Avg. Invested days 44 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/29/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.35B USD | Price to earnings Ratio - | 1Y Target Price 33.23 |
Price to earnings Ratio - | 1Y Target Price 33.23 | ||
Volume (30-day avg) 11 | Beta 1.57 | 52 Weeks Range 9.60 - 25.31 | Updated Date 10/29/2025 |
52 Weeks Range 9.60 - 25.31 | Updated Date 10/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.85 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1376.1% |
Management Effectiveness
Return on Assets (TTM) -28.96% | Return on Equity (TTM) -72.92% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2957809699 | Price to Sales(TTM) 223.46 |
Enterprise Value 2957809699 | Price to Sales(TTM) 223.46 | ||
Enterprise Value to Revenue 197.19 | Enterprise Value to EBITDA 1.12 | Shares Outstanding 134073436 | Shares Floating 85057529 |
Shares Outstanding 134073436 | Shares Floating 85057529 | ||
Percent Insiders 0.48 | Percent Institutions 93.46 |
Upturn AI SWOT
Centessa Pharmaceuticals PLC ADR
Company Overview
History and Background
Centessa Pharmaceuticals PLC ADR (CNTA) was created to accelerate the identification and development of high-impact medicines for patients. It achieves this through a unique asset-centric model.
Core Business Areas
- Drug Development: Focuses on acquiring and developing innovative drug candidates across various therapeutic areas.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Regulatory Approvals: Seeks regulatory approvals from agencies like the FDA for its products.
Leadership and Structure
The leadership team includes experienced executives from the pharmaceutical industry. The company is structured around an asset-centric model, with individual teams focused on specific drug candidates.
Top Products and Market Share
Key Offerings
- Imbruvica (ibrutinib): This is a BTK inhibitor co-developed with AbbVie (ABBV). It has a share of the Bruton's tyrosine kinase (BTK) inhibitor market, competing with others like Calquence (acalabrutinib) by AstraZeneca (AZN).
- Other Pipeline Assets: Centessa is developing a number of other assets across a number of theraputic areas, however none of these have achieved material market share yet.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Innovation and intellectual property are key drivers of success.
Positioning
Centessa aims to differentiate itself through its asset-centric approach, focusing on acquiring promising drug candidates and accelerating their development. Its competitive advantage lies in its experienced management team and streamlined structure.
Total Addressable Market (TAM)
TAM varies significantly depending on the specific therapeutic area. Centessa's positioning depends on the success of its pipeline assets.
Upturn SWOT Analysis
Strengths
- Experienced Management Team
- Asset-Centric Model
- Strong Pipeline
- Innovative Drug Candidates
Weaknesses
- High R&D Costs
- Regulatory Risk
- Commercialization Challenges
- Dependence on Pipeline Success
Opportunities
- Strategic Partnerships
- Expansion into New Therapeutic Areas
- Accelerated Regulatory Pathways
- Acquisition of Promising Assets
Threats
- Competition from Larger Pharmaceutical Companies
- Generic Drug Entry
- Patent Expiry
- Unfavorable Regulatory Changes
Competitors and Market Share
Key Competitors
- ABBV
- AZN
- BMY
- MRK
- PFE
Competitive Landscape
Centessa faces intense competition from larger pharmaceutical companies with more established product portfolios and greater financial resources. Its success depends on the unique value proposition of its pipeline assets.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by pipeline progress, not revenue. Focus on clinical trial milestones.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing key pipeline assets through clinical trials.
Summary
Centessa Pharmaceuticals PLC ADR is a development-stage pharmaceutical company with an asset-centric model. Its future success hinges on the successful development and commercialization of its pipeline assets. Key strengths include an experienced management team and a focus on innovative drug candidates. Investors should closely monitor clinical trial progress and regulatory milestones.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Investment decisions should be based on individual due diligence and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Centessa Pharmaceuticals PLC ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-05-28 | CEO & Director Dr. Saurabh Saha M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 98 | Website https://centessa.com |
Full time employees 98 | Website https://centessa.com | ||
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.